<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8191">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01852604</url>
  </required_header>
  <id_info>
    <org_study_id>IDX-06A-005</org_study_id>
    <nct_id>NCT01852604</nct_id>
  </id_info>
  <brief_title>IDX719 in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Subjects With Chronic Hepatitis C Infection</brief_title>
  <official_title>A Randomized Study to Evaluate the Safety and Efficacy of IDX719 in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Subjects With Chronic Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idenix Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Idenix Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parts A and B of this study are designed to evaluate the safety, tolerability, efficacy and
      pharmacokinetic profiles of IDX719 and simeprevir when administered in combination with
      ribavirin (RBV) for 12 weeks in treatment-naïve, Genotype 1b, 4 and 6 HCV-infected subjects.

      Part C of this study is designed to evaluate the safety, tolerability, efficacy and
      pharmacokinetic profiles of IDX719, simeprevir, TMC647055 and ritonavir (RTV) when
      administered in combinations with or without RBV for 12 weeks in treatment-naïve or
      interferon/RBV-treatment relapsed, Genotype 1a and 1b HCV-infected subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of subjects having adverse events (AEs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antiviral Activity</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects with undetectable plasma HCV RNA at the following timepoints:
Sustained virologic response (SVR4): 4 weeks after the end of treatment
Rapid virologic response (RVR): Week 4 during treatment
Early virologic response (EVR): Week 12 at the end of treatment
SVR8: 8 weeks after the end of treatment
SVR12: 12 weeks after the end of treatment
SVR24: 24 weeks after the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma drug exposure of IDX719, simeprevir, TMC647055 and RTV AUC0-t, Cmax and Ctrough</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">143</enrollment>
  <condition>Chronic Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>Group A (genotypes 1b,4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weeks 1-12 = IDX719 50 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily
Weeks 1-12 = IDX719 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily
Weeks 1-12 = IDX719 150 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (genotypes 1b,4 or 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weeks 1-12 = IDX719 25 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily
Weeks 1-12 = IDX719 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily
Weeks 1-12 = IDX719 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (genotypes 1a, 1b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weeks 1-12 = IDX719 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily plus RTV 30 mg once daily, plus RBV (dosing weight-based, according to product label) twice daily
Weeks 1-12 = IDX719 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily, plus RTV 30 mg once daily, plus RBV (dosing weight-based, according to product label) twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDX719</intervention_name>
    <description>IDX719 will be supplied as 25 mg and 50 mg tablets.</description>
    <arm_group_label>Group A (genotypes 1b,4)</arm_group_label>
    <arm_group_label>Group B (genotypes 1b,4 or 6)</arm_group_label>
    <arm_group_label>Group C (genotypes 1a, 1b)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simeprevir</intervention_name>
    <description>Simeprevir will be supplied as 75 and 150 mg capsules.</description>
    <arm_group_label>Group A (genotypes 1b,4)</arm_group_label>
    <arm_group_label>Group B (genotypes 1b,4 or 6)</arm_group_label>
    <arm_group_label>Group C (genotypes 1a, 1b)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>Ribavirin will be supplied as 200 mg tablets.</description>
    <arm_group_label>Group A (genotypes 1b,4)</arm_group_label>
    <arm_group_label>Group B (genotypes 1b,4 or 6)</arm_group_label>
    <arm_group_label>Group C (genotypes 1a, 1b)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC647055</intervention_name>
    <description>TMC647055 will be supplied as 150 mg capsules.</description>
    <arm_group_label>Group C (genotypes 1a, 1b)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <description>Ritonavir will be supplied as 80 mg/mL oral solution.</description>
    <arm_group_label>Group C (genotypes 1a, 1b)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have Genotype 1a, 1b, 4 or 6 HCV infection.

          -  Documented clinical history compatible with chronic hepatitis C

          -  HCV treatment-naïve or interferon/RBV-treatment relapsed (Part C)

          -  Must agree to use an acceptable double method of birth control (one of which must be
             a barrier method) for at least 6 months after the last dose of study drugs.

        Exclusion Criteria:

          -  Female subjects who are pregnant or breastfeeding.

          -  Body Mass Index (BMI) &gt; 36 kg/m2.

          -  Co-infected with hepatitis B virus or human immunodeficiency virus (HIV).

          -  History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC.

          -  History or signs of decompensated liver disease:  ascites, variceal bleeding, hepatic
             encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal
             hypertension or hepatic insufficiency.

          -  Has one or more known primary or secondary causes of liver disease, other than
             hepatitis C

          -  History of, or active, acute or chronic, liver or biliary injury due to drugs,
             toxins, non-HCV viral hepatitis, gallstones or other etiologies

          -  Donated blood or had significant blood loss 30 days prior to dosing
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 16, 2014</lastchanged_date>
  <firstreceived_date>May 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>chronic hepatitis C</keyword>
  <keyword>antiviral</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
